Advanced Bionics Unveils New Ipad Device Apps for Children with Hearing Impairment

By CIOReview | Monday, August 18, 2014

VALENCIA, CA: Advanced Bionics (AB), a developer of cochlear implant technology and a company of the Sonova Group, has launched two new iPad device apps as part of their growing rehAB range of rehabilitative and educational tools for people with hearing loss, reports Business Wire.

The creative, interactive apps have been specially designed for caregivers or therapists to guide the development of listening and language skills in children with hearing loss ages 4 to 10.

Cochlear implants are sophisticated medical devices that can restore hearing for people with significant hearing loss. To take full advantage of this highly advanced technology, cochlear implant recipients need to devote time and effort to rehabilitation exercises. The new apps are intended to encourage greater compliance by making practice fun and engaging for younger recipients.

AB Listening Adventures is a dynamic app providing children with a fun way to practice listening for words in sentences. The app’s features includes six different story-based games that;  Focus on listening for multiple elements, plurals, pronouns, or minimal pairs; has more than 100 sets of words; Fun sound effects and character voices; and Many opportunities for teaching vocabulary and sentence structure

The colorful, entertaining VocAB Scenes app is designed to help children learn common vocabulary and question forms through listening. The app features;  Six different scenes (outside water fun, beach, pet store, swimming pool, camping, and winter fun); 12 different drag and drop items for each scene; Three different games for each scene to promote listening and language development

“AB is committed to creating the most effective, engaging rehabilitative and educational tools possible.  These unique, new apps are great additions to our innovative rehAB line,” says Carissa Moeggenberg, Senior Manager of Education, Training, and Rehab, Advanced Bionics.